Pediatrics

A new survey shows widespread uncertainty about which vaccines the CDC recommends during pregnancy, underscoring the counseling role pharmacists play.

Vaccine guidance in the US is undergoing a dramatic change, leaving pharmacists uncertain about coverage, authority, and flu-season timing.

Researchers assess the impact of various pneumococcal conjugate vaccines since the introduction of immunization programming.

A new sibling-matched cohort study challenges earlier observational data, offering pharmacists evidence-based reassurance to share with pregnant patients.

AAP challenges HHS as ACIP stalls, leaving pharmacists and health care in limbo on vaccine coverage and respiratory recommendations.

Retracted vaccine-autism study exposes statistical flaws, reigniting hepatitis B birth-dose debate and highlighting why pharmacists must rely on evidence-based data.

This decision marks a milestone in clinical pharmacy as it targets the underlying autoimmune destruction of pancreatic beta cells.

This schedule arrives at a time of unprecedented friction between leading medical societies and federal health agencies.

Alongside malnutrition instances and measles cases, researchers review pneumonia disease burden and immune vulnerability across high-risk pediatric groups.

The executive order calls to realign core childhood vaccine recommendations with scientific evidence and best practices of peer, developed nations.

This regulatory milestone establishes inhaled insulin as the first and only noninjectable mealtime insulin option for children and adolescents.

New FDA label lets linaclotide treat functional constipation in children 2 to 5, with dosing tips, mixing options, and key safety warnings.

Utah protocol streamlines large-volume immunoglobulin for measles-exposed infants as outbreaks surge.

The drug’s indication for uncontrolled chronic spontaneous urticaria is the first biologic medicine of its kind, specifically explored amongst children 2 to 11 years old.

FDA expands Tzield use to age 1 year to delay stage 3 type 1 diabetes, enabling earlier immune intervention.

As population-level introduction of pneumococcal conjugate vaccines has led to an increase in invasive disease, the development of higher-valency vaccines has become a primary solution.

FDA expands lomitapide use to children 2 years and older, highlighting major low-density lipoprotein reductions.

Modeling shows PCV20 in pediatric patients prevents millions of pneumococcal cases and saves billions, reshaping vaccination choices for pharmacists and parents.

Exploring the perspectives of health care professionals, researchers test the feasibility of the Asthma Care from Home project.

Inhaled Technosphere insulin revolutionizes diabetes management for children and pregnant women, addressing treatment adherence and psychological barriers effectively.

The American Academy of Pediatrics responds to recent HHS vaccine guideline changes with its own schedule for childhood and adolescent patients.

Amid evolving recommendations for products like acetaminophen as well as influenza vaccines, researchers revisit the role of pharmacists in addressing adolescents’ cold and flu symptoms.

Medical organizations challenge the government's revised childhood vaccine schedule, urging Congress for immediate oversight and action to protect public health.

Fremanezumab significantly reduces migraine days in children and adolescents, offering a vital preventive option for managing episodic migraines.

This marks the disease’s very first treatment option for pediatric patients looking to manage Menkes and its symptoms.